# Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study

> **NCT02393924** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 311 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT02393924
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-23
- **Primary completion:** 2023-04-19
- **Final completion:** 2023-04-19
- **Target enrollment:** 311 (ACTUAL)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02393924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02393924, "Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02393924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*